Drugs / BIIB107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04593121 | Oct 2020 → Mar 2024 | — | Biogen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04593121 ↗ |
| Modality | Monoclonal antibody | “BIIB107 is a monoclonal antibody (mAb)” NCT04593121 ↗ |
| Route | Subcutaneous | “single and multiple ascending subcutaneous (SC) doses” NCT04593121 ↗ |